Boston Scientific Corporation $BSX Shares Sold by Bollard Group LLC

Posted by Brenda Bartman on Jun 14th, 2026

Boston Scientific logo Bollard Group LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 3.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 19,000,469 shares of the medical equipment provider’s stock after selling 733,104 shares during the period. Boston Scientific accounts for about 45.3% of Bollard Group LLC’s portfolio, making the stock its biggest position. Bollard Group LLC’s holdings in Boston Scientific were worth $1,811,695,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Arrowstreet Capital Limited Partnership grew its position in shares of Boston Scientific by 31.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock worth $1,052,247,000 after buying an additional 2,668,230 shares during the period. Ally Financial Inc. acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $1,049,000. Aptus Capital Advisors LLC grew its position in shares of Boston Scientific by 2.9% during the 4th quarter. Aptus Capital Advisors LLC now owns 78,035 shares of the medical equipment provider’s stock worth $7,441,000 after buying an additional 2,173 shares during the period. Prosight Management LP grew its position in shares of Boston Scientific by 176.0% during the 4th quarter. Prosight Management LP now owns 210,000 shares of the medical equipment provider’s stock worth $20,024,000 after buying an additional 133,900 shares during the period. Finally, FORA Capital LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $1,125,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $46.83 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a twelve month low of $45.99 and a twelve month high of $109.50. The firm’s 50 day moving average price is $56.37 and its two-hundred day moving average price is $74.95. The firm has a market cap of $69.60 billion, a P/E ratio of 19.59, a PEG ratio of 0.88 and a beta of 0.56.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the previous year, the firm posted $0.75 earnings per share. The business’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has initiated a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BSX. Needham & Company LLC reiterated a “buy” rating and set a $77.00 price target on shares of Boston Scientific in a research report on Monday, May 18th. Wells Fargo & Company reiterated an “equal weight” rating and set a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Leerink Partners lowered their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 28th. UBS Group lowered their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Finally, Wolfe Research lowered shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.08.

Get Our Latest Stock Report on Boston Scientific

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.